Top

Published in:

01-04-2010 | Original Article

Evaluation of two group therapies to reduce fear of progression in cancer patients

Authors: Peter Herschbach, Katrin Book, Andreas Dinkel, Petra Berg, Sabine Waadt, Gabriele Duran, Ursula Engst-Hastreiter, Gerhard Henrich

Published in: Supportive Care in Cancer | Issue 4/2010

Abstract

Purpose

This paper aims to evaluate the effects of two psychotherapeutic interventions on dysfunctional fear of progression (FoP) in cancer patients and to investigate illness-specific influences.

Methods

One hundred seventy-four cancer patients were recruited from two rehabilitation clinics and randomly assigned to either a four-session cognitive-behavioral group therapy or a supportive-experiential group therapy. The main outcome criterion was FoP that was assessed with the Fear of Progression Questionnaire (FoP-Q) directly before (T1) and after (T2) the intervention, as well as 3 (T3) and 12 months (T4) after discharge. Secondary outcomes were anxiety, depression, and quality of life that were assessed with the following questionnaires: Questions on Life Satisfaction, Questionnaire for General Health Status, and the Hospital Anxiety and Depression Scale. Patients from the control group (n = 91) who received treatment as usual were recruited 1 year later with the same inclusion criteria and assessed with the FoP-Q at T1, T2, and T4.

Results

Analyses showed a significant main effect for time and a significant interaction for group × time for the main outcome variable. FoP decreased significantly over time in both intervention groups in contrast to the control group that showed only short-term improvements. The interventions were also effective in improving secondary outcomes except general life satisfaction. Analyses of cancer specific influences on FoP indicated a significant influence of disease status, i.e., patients with metastases and recurrence of cancer gained most from the interventions.

Conclusions

Fear of progression, one of the main sources of distress for cancer patients, can be reduced with short psychotherapeutic interventions.

Antoni MH, Wimberly SR, Lechner SC, Kazi A, Sifre T, Urcuyo KR, Phillips K, Smith RG, Petronis VM, Guellati S, Wells KA, Blomberg CCS (2006) Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Am J Psychiatry 163:1791–1797CrossRefPubMed

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders—DSM-IV-TR (4th edition, Text Revision). American Psychiatric Association, Washington, DCCrossRef

Bullinger M, Kirchberger I (1998) SF-36 Fagebogen zum Gesundheitszustand (SF-36 Questionnaire concerning Health Status). Hogrefe: Göttingen, Bern, Toronto, Seattle

Bultz BD, Carlson LE (2006) Emotional distress: the sixth vital sign—future directions in cancer care. Psychooncology 15:93–95CrossRefPubMed

Cohn R (2000) Von der psychoanalyse zur themenzentrierten interaktion. Klett-Cotta, Stuttgart

Coyne JC, Lepore SJ, Palmer SC (2006) Efficacy of psychosocial interventions in cancer care: evidence is weaker than it first looks. Ann Behav Med 32:104–110CrossRefPubMed

Dilling H, Mombour W, Schmidt MH (1994) Internationale klassifikation psychischer störungen. ICD-10 Kapitel V (F). Klinisch-diagnostische leitlinien. Huber, Bern

Edwards AGK, Hulbert-Williams N, Neal RD (2004) Psychological interventions for women with metastatic breast cancer. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD004253. doi:10.1002/14651858.CD004253.pub2

Engst-Hastreiter U, Duran G, Henrich G, Keller M, Waadt S, Berg P, Herschbach P (2004) Fear of progression (FoP) in chronic diseases (rheumatic diseases, cancer and diabetes mellitus)—development of a psychological self-assessment instrument and a group therapy program. Akt Rheumatol 29:83–91CrossRef

10.

Gottlieb BH, Wachala D (2007) Cancer support groups: a critical review of empirical studies. Psychooncology 16:379–400CrossRefPubMed

11.

Härter M, Baumeister H, Reuter K, Jacobi F, Höfler M, Bengel J, Wittchen HJ (2007) Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 76:354–360CrossRefPubMed

12.

Härter M, Reuter K, Aschenbrenner A, Schretzmanna B, Marschner N, Hasenburg A, Weis J (2001) Psychiatric disorders and associated factors in cancer: results of an interview study with patients in inpatient, rehabilitation and outpatient treatment. Eur J Cancer 37:1385–1393CrossRefPubMed

13.

Henrich G, Herschbach P (2000) Questions on life satisfaction (FLZ^M)—a short questionnaire for assessing subjective quality of life. Eur J Psychol Assess 16:150–159CrossRef

14.

Herrmann C, Buss U, Snaith RP (1995) HADS-D - hospital anxiety and depression scale—deutsche version: ein fragebogen zur erfassung von angst und depressivität in der somatischen medizin. Huber, Bern

15.

Herrmann C (1997) International experiences with the hospital anxiety and depression scale—a review of validation data and clinical results. J Psychosom Res 42:17–41CrossRefPubMed

16.

Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Waadt S, Keller M, Ukat R, Henrich G (2005) Fear of progression in diabetes mellitus, cancer and chronic arthritis—psychometric properties of the Fear of Progression Questionnaire (FoP-Q). J Psychosom Res 58:505–511CrossRefPubMed

17.

Herschbach P, Berg P, Engst-Hastreiter U, Waadt S, Duran G, Henrich G (2006) Development and evaluation of a therapy program to cope with fear of progression. Final Research Report for the German Federal Ministry of Education and Research (BMBF) and the German Pension Insurance Administration (VdR)

18.

Herschbach P, Berg P, Waadt S, Duran G, Engst-Hastreiter U, Henrich G, Book K, Dinkel (2009) Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis and cancer. Psychotherapy and Psychosomatics, accepted

19.

Herschbach P, Duran G, Engst-Hastreiter U, Waadt S, Berg P (2006) Gruppentherapeutische behandlung von progredienzangst bei krebspatienten. Verhaltensther Verhaltensmed 27:298–309

20.

Herschbach P, Henrich G, Oberst U (1994) Lebensqualität in der nachsorge. eine evaluationsstudie in der fachklinik für onkologie und lymphologie, bad wildungen-reinhardshausen. Prax Klin Verhaltensmed Rehab 28:241–251

21.

Herschbach P, Keller M, Knight L, Brandl T, Huber B, Henrich G, Marten-Mittag B (2004) Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire. Br J Cancer 91:504–511CrossRefPubMed

22.

Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L (1994) Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer 30A:37–40CrossRefPubMed

23.

Lambert MJ, Bergin AE (1994) The effectiveness of psychotherapy. In: Handbook of psychotherapy and behavior change (4th ed). New York: Wiley: 143-189

24.

Lee-Jones C, Humphris G, Dixon R, Hatcher MB (1997) Fear of cancer recurrence—a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology 6:95–105CrossRefPubMed

25.

Mehnert P, Herschbach P, Berg P, Henrich G, Koch U (2006) Progredienzangst bei brustkrebspatientinnen—validierung der kurzform des progredienzangstfragebogens (PA-F-KF). Z Psychosom Med Psychother 52:274–288PubMed

26.

Meyer TJ, Mark MM (1995) Effects of psychosocial interventions with adult cancer patients: A meta-analysis of randomized experiments. Health Psychol 14:101–108CrossRefPubMed

27.

Newell SA, Sanson-Fisher RW, Savolainen NJ (2002) Systematic review of psychological therapies for cancer patients: overview and recommendation for future research. J Natl Cancer Inst 94:558–584PubMed

28.

Northouse LL (1981) Mastectomy patients and the fear of cancer recurrence. Cancer Nurs 4:213–220CrossRefPubMed

29.

Osborn RL, Demoncada AC, Feuerstein M (2006) Psychological interventions for depression, anxiety, and quality of life in cancer survivors: a meta-analysis. Int J Psychiatry Med 36:13–24CrossRefPubMed

30.

Payne DK, Hoffman RG, Theodoulou M, Dosik M, Massie MJ (1999) Screening for anxiety and depression in women with breast cancer. Psychosomatics 40:64–69PubMed

31.

Sareen J, Cox BJ, Clara I, Asmundson GJG (2005) The relationship between anxiety disorders and physical disorders in the U.S. national comorbidity survey. Depress Anxiety 21:193–202CrossRefPubMed

32.

Sellick SM, Edwardson AD (2007) Screening new cancer patients for psychological distress using the hospital anxiety and depression scale. Psychooncology 16:534–542CrossRefPubMed

33.

Sheard T, Maguire P (1999) The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 80:1770–1780CrossRefPubMed

34.

SPSS Inc. SPSS 15.0 Command Syntax Reference. Chicago, IL: SPSS Inc; 2006.

35.

Urbaniak GC, Plous S (2007) Research Randomizer. Available from: http://www.randomizer.org

36.

Van’t Spijker A, Trijsburg RW, Duivenvoorden HJ (1997) Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med 59:280–293PubMed

37.

Wampold BE, Mondin GW, Moody M, Stich F, Benson K, Ahn H (1997) A meta-analysis of outcome studies comparing bona fide psychotherapies: Empirically, “all must have prizes”. Psychol Bull 122:203–215CrossRef

38.

Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10:19–28CrossRefPubMed

Title: Evaluation of two group therapies to reduce fear of progression in cancer patients
Authors: Peter Herschbach
Katrin Book
Andreas Dinkel
Petra Berg
Sabine Waadt
Gabriele Duran
Ursula Engst-Hastreiter
Gerhard Henrich
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 4/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0696-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2010

Ways of talking about illness and prognosis in palliative cancer care consultations—two interactional frames

“It makes you feel so full of life” LiveWell, a feasibility study of a personalised lifestyle programme for colorectal cancer survivors

Development and feasibility assessment of telephone-delivered supportive care to improve outcomes for patients with colorectal cancer: pilot study of the CONNECT intervention

Validation of the Portuguese version of Functional Assessment of Cancer Therapy-Fatigue (FACT-F) in Brazilian cancer patients

Quality of life, anxiety, and depression in Turkish colorectal cancer patients

A qualitative study of decision-making by breast cancer patients about telling their children about their illness

Keynote webinar | Spotlight on antibody–drug conjugates in cancer